Strategic Partnerships ABL Bio has active collaboration momentum with pharma leaders (Lilly, GSK licensing, NovaBridge) to expand its Grabody platform and ADC pipeline, indicating strong inbound and co-development sales opportunities across oncology and neurodegeneration.

BBB Delivery Advantage Grabody-B’s blood-brain barrier penetration capability positions ABL Bio to target CNS indications with high unmet need, presenting a compelling value proposition for neurodegenerative programs and CNS-focused partnerships.

Diversified Modalities A robust bispecific platform portfolio Grabody-T Grabody-I Grabody-B enables collaboration across immuno-oncology and neurodegeneration, allowing BD teams to propose multi-modality licensing, co-development, and asset monetization strategies.

Financial Backing Recent $55M financing from Eli Lilly and ongoing revenue indicates solid financial runway to accelerate partnerships, expand pipeline, and engage in larger strategic deals without immediate funding constraints.

Global Expansion Active global partnerships and licensing activity suggest opportunities to enter regional deals, joint ventures, or regional development rights, especially in Greater China and Korea, leveraging existing collaboration footprints.